Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. Itch exists on a spectrum, according ...

Barclays (LON: BARC) has initiated coverage on Galderma Group AG (SIX: GALD) and Zealand Pharma (NASDAQ: ZEAL) with Overweight ratings, citing distinct growth dri ...

The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, ...

Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year ...

Fintel reports that on July 1, 2025, Cantor Fitzgerald initiated coverage of Trevi Therapeutics (NasdaqGM:TRVI) with a ...

Galderma, a pure-play dermatology category leader, has announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with ...

Galderma begins 2 new clinical trials to investigate efficacy and safety of nemolizumab to treat patients with systemic sclerosis: Zug, Switzerland Friday, June 27, 2025, 13:00 Hr ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients ...